Bristol Sets Positive, But Hesitant Tone About Nivolumab Trials
This article was originally published in The Pink Sheet Daily
The New York pharma talked about its anti-PD-1 drug for most of its year-end conference call, but managed to say very little about the success of the drug so far in clinical trials, disappointing analysts and investors.
You may also be interested in...
Merck plans to enrich its Phase II study for MK-3475 with patients whose tumors express PD-L1; Bristol would take all comers in its Phase I/II trial of nivolumab.
Lung cancer wasn’t viewed traditionally as a tumor that would respond to immunotherapy. But with checkpoint inhibitor data looking promising, big pharma is diving in and prioritizing the disease, reeled in by the large patient population and high unmet need.
Two companies in the biopharma space began trading publicly this week, one to pay off debt, the other to fund an early-stage pipeline.